Aranidipine (MPC-1304), a new dihydropyridine calcium antagonist: A review of its antihypertensive action

Cardiovascular Drug Reviews

Volumn 14, Issue 1, 1996, Pages 1-16

  Ohashi, Kyoichi ^a   Ebihara, Akio ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Antihypertensive agent; Aranidipine; Calcium channel antagonist; Calcium channel antagonistAranidipine

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARANIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DILTIAZEM; DIURETIC AGENT; DRUG METABOLITE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; POTASSIUM; SODIUM;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ATHEROGENESIS; BLOOD PRESSURE; CALCIUM ANTAGONISM; CHOLESTEROL BLOOD LEVEL; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOXICITY; ELECTROPHYSIOLOGY; ESSENTIAL HYPERTENSION; FEEDING; GERIATRIC PATIENT; HEADACHE; HEMODYNAMICS; HOT FLUSH; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR SYSTEM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VASODILATATION;

EID: 0030035814     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1996.tb00310.x     Document Type: Review

References (48)

1. Arakawa K, Iimura O, Yoshinaga K, et al. Effect of MPC-1304, Ca antagonist, on circadian rhythm of blood pressure in patients with essential hypertension - Double-blind comparative study of once a day and twice a day administration. J Clin Therap Med (Suppl 6) 1993,9:3-23.
2. Arakawa K, Iimura O, Yoshinaga K, et al. Pilot study on the efficacy and safety of MPC-1304 as monotherapy in patients with essential hypertension. J Clin Therap Med (Suppl 6) 1993;9:25-40.
3. Arakawa K, Iimura O, Onodera S, et al. Evaluation of the optimum dose for MPC-1304 in patients with essential hypertension. J Clin Therap Med (Suppl 6) 1993;9:41-57.
4. Arakawa K, Iimura O, Onodera S, et al. Evaluation of the antihypertensive effect and safety of MPC-1304, used in combination with a diuretic or β-blocker, in patients with essential hypertension J Clin Therap Med (Suppl 6) 1993,9:59-83.
5. Arakawa K, Iimura O, Onodera S, et al. The efficacy and tolerability of MPC-1304 in a long-term treatment with essential hypertension. J Clin Therap Med (Suppl 6) 1993;9:85-108.
6. Arakawa K, Kajiyama G, Kusukawa R, et al. Effect of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins, and serum glucose metabolism in patients with essential hypertension. J Clin Therap Med (Suppl 6) 1993;9:179-190.
7. Arakawa K, Iimura O, Onodera S, et al. Clinical evaluation of MPC-1304 on essential hypertension - A double-blind study comparing with nicardipine-retard. J Clin Therap Med 1993;9:1829-1860.
8. Aso S, Sueta S, Kajiwara Y, et al. Reproductive and developmental toxicity studies of MPC-1304 (I): Fertility study in rats by oral administration. Jpn Pharmacol Ther (Suppl 4) 1993;21:1083-1093.
9. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1977,17:149-166.
10. 2+ entry blocker, on alpha-adrenoceptor-mediated pressor responses in pithed rats. Eur J Pharmacol 1993;238:283-289.
11. The Joint National Committee on Detection Evaluation of High Blood Pressure. The fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 1993;153:154-183.
12. Kanda A, Haruno A, Miyake H, Nagasaka M Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs. J Cardiovasc Pharmacol 1992,20:723-730.
13. Kanda A, Haruno A, Miyoshi K. et al. Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: Comparison with other calcium antagonists. J Cardiovasc Pharmacol 1993;22:167-175.
14. Kumagai Y, Fujimura A, Shiga T, Sunaga K, Ohashi K, Ebihara A. Pharmacokinetics and pharmacodynamics of a new calcium channel blocker, MPC-1304, in hypertensive subjects. Am J Ther 1996;3:1-4.
15. Miyoshi K, Kanda A, Miyake H, Ichihara K, Kamei H, Nagasaka M. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action. Eur J Pharmacol 1993;238:139-148.
16. Miyoshi K, Miyake H, Ichihara K, Kamei H, Nagasaka M Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine. 1995 (submitted).
17. Momose Y, Nishigaki J, Motoji N, et al. Pharmacokinetic studies of MPC-1304 (2): Distribution, transfer into the fetus and milk, and effect on liver metabolizing enzymes after single or multiple administration to rats. Jpn Pharmacol Ther (Suppl 4) 1993;21:1181-1206.
18. Nakano S, Yada H, Kuwata M, Tanaka G, Hayashi T Single dose toxicity studies of MPC-1304 in mice, rats, and dogs. Jpn Pharmacol Ther (Suppl 4) 1993;21:931-937.
19. Nakano S, Yada H, Hirota T, Kurokawa K, Irimura K. A thirteen-week oral repeated dose toxicity study of MPC-1304 in beagle dogs. Jpn Pharmacol Ther (Suppl 4) 1993;21:977-1011.
20. Niwa M, Shigematsu K, Maeda T, et al Effects of MPC-1304, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats. Arch Int Pharmacodyn Ther 1994,327:309-329.
21. Ogihara T, Higashimori K, Nagano M, et al. Pharmacokinetics and antihypertensive effects of MPC-1304, a calcium channel blocking agent, in elderly patients with essential hypertension. J Clin Therap Med (Suppl 6) 1993;9:109-116.
22. Ohashi K, Sudo T, Sakamoto K, et al. Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker. Int J Clin Pharmacol Ther Toxicol 1992;30:271-274.
23. Ohkubo M, Katsuta T, Masunaga A, et al. A fifty-two week oral repeated dose toxicity study of MPC-1304 in dogs Jpn Pharmacol Ther (Suppl 4) 1993;21:1041-1081.
24. Ohno S, Komatsu O, Mizukoshi K, et al. Synthesis of asymmetric 4-aryl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylates with vasodilating and antihypertensive activities. Chem Pharm Bull 1986;34:1589-1606.
25. Ohno S, Komatsu O, Mizukoshi K, Akimatsu N, Oda N. Synthesis of metabolites of MPC-1304, a new calcium antagonist, and related compounds and optical resolution of MPC-1304 and related compounds J Pharmacobio-Dyn 1991;14s:108
26. Ohuchida A, Furukawa A, Kashihara A, Omae S. Mutagenicity studies of MPC-1304. Jpn Pharmacol Ther (Suppl 4) 1993;21:1159-1168.
27. Okazaki S, Ueno H, Anabuki K, et al. A 3-month oral toxicity study of MPC-1304 in rats with a recovery period of one month. Jpn Pharmacol Ther (Suppl 4) 1993;21:947-976.
28. Okazaki S, Hatayama K, Tamura K, Hasegawa H, Kawase Y. A 12-month oral toxicity study of MPC-1304 in rats with a recovery period of one month. Jpn Pharmacol Ther (Suppl 4) 1993;21:1013-1040.
29. Okumura K, Ichihara K, Nagasaka M, Oda N, Tajima K. Calcium entry blocking activities of MPC-1304 and of its enantiomers and metabolites. Eur J Pharmacol 1993;235:69-74.
30. Oribe H, Sugimoto K, Kumagai Y, et al. Pharmacodynamic and pharmacological effects of MPC-1304, a new calcium channel blocker, in healthy subjects - Results of single oral administration. Jpn J Clin Pharmacol Ther 1990;21:507-512.
31. Oribe H, Sugimoto K, Kumagai Y, et al. Pharmacodynamic and pharmacological effects of MPC-1304, a new calcium channel blocker, in healthy subjects - Results of multiple oral administration. Jpn J Clin Pharmacol Ther 1990;21.513-520.
32. Oribe H, Nakashima H, Shitou T, et al. Effect of food and gastric acidity on the pharmacokinetics of MPC-1304, a new calcium channel blocker. Jpn J Clin Pharmacol Ther 1991;22:757-766.
33. Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 1985;34:2549-2553.
34. Sakamoto N, Iguchi A, Tamagawa T. Antihypertensive effect and effect on glucose tolerance of MPC-1304 in patients with essential hypertension associated with diabetes mellitus. J Clin Therap Med (Suppl 6) 1993;9:191-203.
35. Saruta T, Iimura O, Abe K, et al. Clinical efficacy of MPC-1304 in treatment of hypertension associated with renal impairment. J Clin Therap Med (Suppl 6) 1993;9:151-167.
36. Saruta T, Iimura O, Abe K, et al. Clinical efficacy of MPC-1304 in treatment of renovascular hypertension. J Clin Therap Med (Suppl 6) 1993;9:169-177.
37. Shimadzu H, Ishida S, Yamazaki E, Fujioka M, Yamakita O, Yamamoto H. Reproductive and developmental toxicity studies of MPC-1304 (III): Teratological study in mice by oral administration. Jpn Pharmacol Ther (Suppl 4) 1993;21:1115-1124.
38. Sorkin EM, Clissold SP, Brogden RN. Nifedipine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in ischemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985;30:182-274.
39. 2+ channel by MPC-1304, a novel calcium antagonist in guinea pig hearts. Arch Int Pharmacodyn Ther 1996 (in press).
40. Suzuki S, Hashimoto T, Kusano S, Kapuku K, Utsunomiya T, Yano K. Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension. Arzneimittelforschung 1993;43:1152-1156.
41. Suzuki H, Kageyama Y, Hayashi K, Saruta T. Pharmacokinetic study of MPC-1304 in hypertensive patients with renal failure after multiple doses. J Clin Therap Med (Suppl 6) 1993;9:137-149.
42. Umemura T, Katsumata Y, Takigami H, Yamakita O, Yamamoto H. Reproductive and developmental toxicity studies of MPC-1304 (IV): Teratological study in rabbits by oral administration. Jpn Pharmacol Ther (Suppl 4) 1993;21:1125-1137.
43. Yamakita O, Koida M, Shinomiya M, Katayama S, Yoshida R. Reproductive and developmental toxicity studies of MPC-1304 (II): Teratological study in rats by oral administration. Jpn Pharmacol Ther (Suppl 4) 1993;21:1095-1113.
44. Yamakita O, Koida M, Shinomiya M, Ikebuchi K, Yoshida R. Reproductive and developmental toxicity studies of MPC-1304 (V): Peri- and postnatal study in rats by oral administration. Jpn Pharmacol Ther (Suppl 4) 1993;21:1139-1157
45. Yamamoto Y, Uda K, Matsushita H, Shindo T, Nagasaka M. Pharmacokinetic studies of MPC-1304 (1): Absorption, excretion in rats. Jpn Pharmacol Ther (Suppl 4) 1993;21:1169-1179.
46. Yamamoto Y, Uda K, Matsushima E, Shindo T, Nagasaka M. Pharmacokinetic studies of MPC-1304 (3): Metabolism in rats. Jpn Pharmacol Ther (Suppl 4) 1993;21:1207-1221.
47. Yamamoto Y, Uda K, Mita A, et al. Pharmacokinetic studies of MPC-1304 (4): Dose response, animal differences, protein binding. Jpn Pharmacol Ther (Suppl 4) 1993;21:1223-1236.
48. Yoshinaga K, Onodera S, Ebihara A, et al. Clinical evaluation of MPC-1304 in patients with severe hypertension. J Clin Therap Med (Suppl 6) 1993;9:117-136.